phthalylsulfathiazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-infectives, sulfonamides 2158 85-73-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phthalylsulfathiazole
  • cremothalidine
  • enteramida
  • entexidina
  • phtalazol
  • phthalazol
  • phthalylnorsulfazole
  • phthalylsulfonazole
  • phthalylsulphathiazole
  • sulfaphthalazole
  • sulfathalidine
  • sulphaphthalyl
  • phthalylsulfathiazole sodium
  • phthalylsulfathiazole monosodium salt
minor descriptor (63-86); on-line & INDEX MEDICUS search SULFATHIAZOLES (66-86); RN given refers to parent cpd
  • Molecular weight: 403.43
  • Formula: C17H13N3O5S2
  • CLOGP: 1.25
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 125.46
  • ALOGS: -4.37
  • ROTB: 5

Drug dosage:

DoseUnitRoute
9 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.625 Moderate 0.67
caco2-efflux Caco-2 efflux ratio (BA/AB) 10 Moderate 0.67
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.298 10^-6 cm/s Moderate 0.67
dh-clint Dog hepatocyte intrinsic clearance 2.183 uL/min/10^6 cells Moderate 0.67
dppb Dog plasma protein binding (% unbound) 6.170 % Moderate 0.67
fcs-ppb Fetal calf serum protein binding (% unbound) 11.650 % Moderate 0.67
herg hERG pIC50 4.426 pIC50 Moderate 0.67
hh-clint Human hepatocyte intrinsic clearance 1.109 uL/min/10^6 cells Moderate 0.67
hlm-clint Human liver microsomal intrinsic clearance 3.090 uL/min/mg protein Moderate 0.67
hppb Human plasma protein binding (% unbound) 1.770 % Moderate 0.67
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 55
kinase-selectivity-class ACVR2A,AURKA,AURKB,AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K3,MAP2K6,MAPK12,MAPK7,MARK4,MTOR,PDK4,PRKDC,SIK2,STK33,SYK,TEK,TTK,ULK1 26
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.600 Moderate 0.67
mh-clint Mouse hepatocyte intrinsic clearance 3.475 Moderate 0.67
mppb Mouse plasma protein binding (% unbound) 7.830 Moderate 0.67
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.252 Moderate 0.67
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 4.390 % Moderate 0.67
rh-clint Rat hepatocyte intrinsic clearance 2.399 uL/min/10^6 cells Moderate 0.67
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.110 % Moderate 0.67
rppb Rat plasma protein binding (% unbound) 1.240 % Moderate 0.67
solubility-dd Solubility at pH 7.4 in DMSO 952.796 uM Moderate 0.67

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigus 4626.61 434.30 5591 299796 321273 90001787
Systemic lupus erythematosus 4179.85 434.30 5595 299792 356301 89966759
Glossodynia 3904.20 434.30 5098 300289 316681 90006379
Hand deformity 3267.58 434.30 4483 300904 291879 90031181
Wound 2954.98 434.30 4323 301064 298657 90024403
Abdominal discomfort 2787.04 434.30 5412 299975 471916 89851144
Alopecia 2686.72 434.30 5444 299943 489627 89833433
Pericarditis 2447.00 434.30 3725 301662 266426 90056634
Swelling 2326.08 434.30 4654 300733 414404 89908656
Anti-cyclic citrullinated peptide antibody positive 2195.55 434.30 3299 302088 233134 90089926
Arthropathy 2161.71 434.30 4175 301212 362067 89960993
Synovitis 1988.14 434.30 3794 301593 325958 89997102
Discomfort 1977.00 434.30 3411 301976 270924 90052136
Contraindicated product administered 1930.59 434.30 3684 301703 316455 90006605
Helicobacter infection 1722.61 434.30 2888 302499 223962 90099098
Duodenal ulcer perforation 1675.94 434.30 2814 302573 218474 90104586
Rheumatoid factor positive 1659.33 434.30 2442 302945 169208 90153852
Maternal exposure during pregnancy 1574.34 434.30 3633 301754 356430 89966630
Rheumatic fever 1461.78 434.30 2166 303221 150955 90172105
Infusion related reaction 1429.59 434.30 3833 301554 412947 89910113
Hepatic enzyme increased 1386.41 434.30 3463 301924 357273 89965787
Type 2 diabetes mellitus 1308.14 434.30 2407 302980 200837 90122223
Product use issue 1215.90 434.30 3118 302269 326801 89996259
Swollen joint count increased 1182.18 434.30 1656 303731 109550 90213510
Liver injury 1104.73 434.30 2026 303361 168541 90154519
Psoriatic arthropathy 1098.31 434.30 2395 302992 225940 90097120
Folliculitis 1040.78 434.30 2194 303193 202159 90120901
Blood cholesterol increased 1010.68 434.30 2191 303196 205821 90117239
Muscle injury 971.66 434.30 1958 303429 174696 90148364
Irritable bowel syndrome 940.02 434.30 2125 303262 205323 90117737
Hypersensitivity 929.08 434.30 3499 301888 451178 89871882
Blister 915.98 434.30 2388 302999 252610 90070450
Fall 914.56 434.30 247 305140 481563 89841497
Drug intolerance 907.46 434.30 3436 301951 444155 89878905
Joint swelling 868.55 434.30 3674 301713 499626 89823434
Injury 858.03 434.30 1989 303398 195360 90127700
Back pain 855.26 434.30 54 305333 317121 90005939
Impaired healing 808.13 434.30 2161 303226 232038 90091022
Treatment failure 784.11 434.30 2528 302859 301400 90021660
Fibromyalgia 777.98 434.30 1968 303419 204301 90118759
Death 758.76 434.30 295 305092 456256 89866804
Hypotension 753.86 434.30 102 305285 325295 89997765
Erythema 748.40 434.30 4 305383 229242 90093818
General physical health deterioration 728.02 434.30 2737 302650 352378 89970682
Sleep disorder due to general medical condition, insomnia type 713.93 434.30 1432 303955 127262 90195798
Hip arthroplasty 690.74 434.30 1053 304334 75155 90247905
Nausea 680.56 434.30 1734 303653 1108582 89214478
Mobility decreased 670.51 434.30 2112 303275 248622 90074438
Ill-defined disorder 629.38 434.30 1698 303689 183193 90139867
Pain 614.24 434.30 5568 299819 990773 89332287
Therapeutic product effect decreased 601.72 434.30 2179 303208 275392 90047668
Joint range of motion decreased 595.63 434.30 1373 304014 134270 90188790
Lip dry 572.58 434.30 1134 304253 99821 90223239
Musculoskeletal stiffness 570.83 434.30 2241 303146 294291 90028769
Myalgia 566.70 434.30 4 305383 175121 90147939
Knee arthroplasty 562.00 434.30 1007 304380 82175 90240885
Facet joint syndrome 552.97 434.30 1101 304286 97288 90225772
Stomatitis 533.51 434.30 2082 303305 272616 90050444
Intentional product use issue 478.55 434.30 1713 303674 215179 90107881
Lower respiratory tract infection 472.24 434.30 1882 303505 248777 90074283
Peripheral venous disease 470.21 434.30 938 304449 82983 90240077
Deep vein thrombosis postoperative 451.39 434.30 836 304551 69973 90253087
Blood pressure increased 451.37 434.30 64 305323 197153 90125907
Wound infection 438.64 434.30 1051 304336 105351 90217709

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigus 3380.51 587.61 3054 218421 211516 110156308
Systemic lupus erythematosus 3090.71 587.61 3137 218338 251201 110116623
Glossodynia 3051.47 587.61 2929 218546 219075 110148749
Hand deformity 2992.09 587.61 2877 218598 215629 110152195
Wound 2518.09 587.61 2708 218767 231729 110136095
Pericarditis 2486.05 587.61 2606 218869 216508 110151316
Anti-cyclic citrullinated peptide antibody positive 2280.59 587.61 2284 219191 179700 110188124
Synovitis 2220.24 587.61 2737 218738 271355 110096469
Helicobacter infection 1992.38 587.61 2124 219351 179753 110188071
Swelling 1947.82 587.61 2917 218558 348124 110019700
Alopecia 1909.45 587.61 2950 218525 361803 110006021
Duodenal ulcer perforation 1891.41 587.61 2044 219431 175656 110192168
Arthropathy 1726.88 587.61 2481 218994 285041 110082783
Rheumatoid factor positive 1718.14 587.61 1690 219785 129950 110237874
Abdominal discomfort 1707.57 587.61 2925 218550 390933 109976891
Rheumatic fever 1650.75 587.61 1601 219874 120978 110246846
Hepatic enzyme increased 1522.08 587.61 2482 218993 318410 110049414
Discomfort 1511.41 587.61 2001 219474 212706 110155118
Type 2 diabetes mellitus 1433.49 587.61 1770 219705 175462 110192362
Folliculitis 1418.59 587.61 1713 219762 165940 110201884
Infusion related reaction 1357.45 587.61 2600 218875 378562 109989262
Contraindicated product administered 1342.49 587.61 2040 219435 246227 110121597
Maternal exposure during pregnancy 1322.94 587.61 2055 219420 252828 110114996
Irritable bowel syndrome 1284.58 587.61 1613 219862 162602 110205222
Muscle injury 1283.99 587.61 1495 219980 139312 110228512
Psoriatic arthropathy 1231.92 587.61 1733 219742 195028 110172796
Swollen joint count increased 1223.36 587.61 1144 220331 82517 110285307
Blister 1207.42 587.61 1853 219622 225523 110142301
Fibromyalgia 1182.46 587.61 1580 219895 169329 110198495
Impaired healing 1161.50 587.61 1685 219790 195032 110172792
Joint swelling 1152.38 587.61 2657 218818 440188 109927636
Hypersensitivity 1114.44 587.61 2481 218994 401517 109966307
Injury 1064.76 587.61 1531 219944 175734 110192090
Blood cholesterol increased 1059.19 587.61 1561 219914 183224 110184600
Liver injury 1031.82 587.61 1385 220090 149028 110218796
Drug intolerance 1011.26 587.61 2397 219078 404115 109963709
Lip dry 981.94 587.61 1104 220371 98979 110268845
Sleep disorder due to general medical condition, insomnia type 978.38 587.61 1131 220344 104512 110263312
Facet joint syndrome 946.36 587.61 1066 220409 95762 110272062
Ill-defined disorder 921.81 587.61 1341 220134 155512 110212312
Mobility decreased 899.10 587.61 1664 219811 235758 110132066
Joint range of motion decreased 888.14 587.61 1156 220319 120676 110247148
Therapeutic product effect decreased 831.02 587.61 1636 219839 242680 110125144
Peripheral venous disease 808.20 587.61 918 220557 83199 110284625
Treatment failure 783.15 587.61 1720 219755 275514 110092310
Stomatitis 782.00 587.61 1693 219782 268549 110099275
Hypotension 765.34 587.61 80 221395 523769 109844055
Death 725.45 587.61 248 221227 698621 109669203
C-reactive protein abnormal 701.81 587.61 1067 220408 128628 110239196
Lower respiratory tract infection 686.10 587.61 1508 219967 241598 110126226
Obesity 680.15 587.61 979 220496 112372 110255452
Night sweats 652.27 587.61 1050 220425 132933 110234891
Musculoskeletal stiffness 650.94 587.61 1609 219866 278213 110089611
Bursitis 650.11 587.61 1031 220444 128887 110238937
Product use issue 649.27 587.61 1719 219756 309976 110057848
Hip arthroplasty 615.58 587.61 655 220820 55158 110312666
Breast cancer stage III 611.40 587.61 773 220702 78344 110289480
Deep vein thrombosis postoperative 600.11 587.61 665 220810 58626 110309198
Wound infection 596.09 587.61 845 220630 95620 110272204

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AB02 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Sulfonamides

Related Drugs by ATC class:

A07AB Sulfonamides 2 drugs
succinylsulfathiazolesulfaguanidine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.73 acidic
pKa2 6.8 acidic
pKa3 13.12 acidic
pKa4 1.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D02440 KEGG_DRUG
C0070975 UMLSCUI
CHEBI:9336 CHEBI
CHEMBL1524273 ChEMBL_ID
DB13248 DRUGBANK_ID
C100300 MESH_SUPPLEMENTAL_RECORD_UI
4806 PUBCHEM_CID
13907 IUPHAR_LIGAND_ID
4175 INN_ID
6875L5852V UNII
33632 RXNORM
002838 NDDF
16359004 SNOMEDCT_US
6875L5852V INXIGHT DRUGS

Pharmaceutical products:

None